Pulse Biosciences, Inc. (NASDAQ:PLSE – Get Free Report)’s stock price traded down 8.1% during mid-day trading on Tuesday . The company traded as low as $18.83 and last traded at $18.87. 136,419 shares were traded during mid-day trading, a decline of 37% from the average session volume of 214,960 shares. The stock had previously closed at $20.53.
Analyst Upgrades and Downgrades
Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a report on Tuesday, August 6th.
View Our Latest Stock Report on Pulse Biosciences
Pulse Biosciences Stock Performance
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of PLSE. BNP Paribas Financial Markets grew its position in shares of Pulse Biosciences by 63.6% during the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after purchasing an additional 2,952 shares in the last quarter. Quest Partners LLC bought a new position in Pulse Biosciences in the 2nd quarter valued at approximately $91,000. Price T Rowe Associates Inc. MD bought a new position in Pulse Biosciences in the 1st quarter valued at approximately $88,000. Cetera Advisors LLC bought a new position in Pulse Biosciences in the 1st quarter valued at approximately $109,000. Finally, PNC Financial Services Group Inc. bought a new position in Pulse Biosciences in the 4th quarter valued at approximately $242,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Stories
- Five stocks we like better than Pulse Biosciences
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- How Investors Can Find the Best Cheap Dividend Stocks
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- The Basics of Support and Resistance
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.